{
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "document": "Zimmerman_et_al.__2023_",
  "verification_stats": {
    "total_extracted": 1,
    "verified": 0,
    "rejected": 1,
    "verification_rate": 0.0
  },
  "verified_evidence": [],
  "rejected_evidence": [
    {
      "id": 1,
      "quote": "because it is not subject to mutations to the A (H3 N2) glycosylation binding site that reduce the effectiveness of egg based vaccines.",
      "reason": "does not support claim",
      "original_explanation": "This quote supports the claim by indicating that recombinant technology avoids certain mutations that can limit the effectiveness of traditional (egg-based) vaccines, suggesting a broader or more robust immune response."
    }
  ],
  "model_used": "gpt-4.1"
}